Form 4: MAIA Biotechnology Officer Buys Stock

MAIA Biotechnology's Chief Scientific Officer, Sergei Gryaznov, acquired 2,000 shares of common stock on June 1, 2026, at a price of $1.345 per share.

Summary

• Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, Inc., purchased 2,000 shares of common stock.
• The transaction occurred on June 1, 2026, with shares acquired at a price of $1.345 each.
• Following this transaction, Mr. Gryaznov beneficially owns 46,511 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine insider stock purchase without additional context or significant financial disclosures.

Positives

• Insider buying activity, as indicated by the Chief Scientific Officer's purchase, can signal confidence in the company's future prospects.
• The purchase of 2,000 shares at a specific price point provides a data point for current valuation.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by scientific officers in the biotechnology sector, can sometimes reflect a belief in the company's pipeline or upcoming research developments, though this filing provides no explicit details to confirm such a sentiment.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal of confidence from a key executive, potentially influencing sentiment.
• Employees may interpret the purchase as a sign of internal belief in the company's future, though direct impact is minimal.

Key Dates

Keywords

MAIA Biotechnology, Form 4, Insider Trading, Stock Purchase, Sergei Gryaznov, Chief Scientific Officer, Beneficial Ownership